Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2012
Filed with the SEC on Mar 1, 2013 and accepted by EDGAR at Mar 1, 2013, 21:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-10-01 to 2012-12-31 | $334.0m | us-gaap:Revenues |
| Revenue | 12 months2012-01-01 to 2012-12-31 | $1.53bn | us-gaap:Revenues |
| Cost of revenue | 3 months2012-10-01 to 2012-12-31 | $75.6m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 12 months2012-01-01 to 2012-12-31 | $236.7m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2012-10-01 to 2012-12-31 | $213.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2012-01-01 to 2012-12-31 | $806.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-10-01 to 2012-12-31 | $110.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2012-01-01 to 2012-12-31 | $436.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-10-01 to 2012-12-31 | −$77.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2012-01-01 to 2012-12-31 | $2.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-10-01 to 2012-12-31 | $3.8m | us-gaap:InterestExpense |
| Interest expense | 12 months2012-01-01 to 2012-12-31 | $16.7m | us-gaap:InterestExpense |
| Income tax | 3 months2012-10-01 to 2012-12-31 | −$2.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2012-01-01 to 2012-12-31 | $38.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-10-01 to 2012-12-31 | −$76.1m | us-gaap:NetIncomeLoss |
| Net income | 12 months2012-01-01 to 2012-12-31 | −$107.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-10-01 to 2012-12-31 | −$0.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2012-01-01 to 2012-12-31 | −$0.50 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-10-01 to 2012-12-31 | −$0.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2012-01-01 to 2012-12-31 | −$0.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-10-01 to 2012-12-31 | 214,607,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2012-01-01 to 2012-12-31 | 211,946,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2012-01-01 to 2012-12-31 | $267.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2012-01-01 to 2012-12-31 | $71.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-12-31 | $489.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-12-31 | $1.59bn | us-gaap:AssetsCurrent |
| Total assets | At period end2012-12-31 | $2.76bn | us-gaap:Assets |
| Current liabilities | At period end2012-12-31 | $432.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-12-31 | $1.52bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-12-31 | $999.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-13-000009. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.